216 related articles for article (PubMed ID: 33373040)
21. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts.
Muro Y; Nakanishi H; Katsuno M; Kono M; Akiyama M
Clin Chim Acta; 2017 Sep; 472():1-4. PubMed ID: 28687351
[TBL] [Abstract][Full Text] [Related]
22. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.
Herbert MK; Stammen-Vogelzangs J; Verbeek MM; Rietveld A; Lundberg IE; Chinoy H; Lamb JA; Cooper RG; Roberts M; Badrising UA; De Bleecker JL; Machado PM; Hanna MG; Plestilova L; Vencovsky J; van Engelen BG; Pruijn GJ
Ann Rheum Dis; 2016 Apr; 75(4):696-701. PubMed ID: 25714931
[TBL] [Abstract][Full Text] [Related]
23. Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies.
Ikenaga C; Findlay AR; Goyal NA; Robinson S; Cauchi J; Hussain Y; Wang LH; Kershen JC; Beson BA; Wallendorf M; Bucelli RC; Mozaffar T; Pestronk A; Weihl CC
Ann Clin Transl Neurol; 2021 Mar; 8(3):571-578. PubMed ID: 33556224
[TBL] [Abstract][Full Text] [Related]
24. Sporadic inclusion body myositis and primary Sjogren's syndrome: an overlooked diagnosis.
Chung SH; Bent EI; Weiss MD; Gardner GC
Clin Rheumatol; 2021 Oct; 40(10):4089-4094. PubMed ID: 33884496
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and Clinical Development of Sporadic Inclusion Body Myositis and Polymyositis With Mitochondrial Pathology: A Single-Center Retrospective Analysis.
Winkler M; von Landenberg C; Kappes-Horn K; Neudecker S; Kornblum C; Reimann J
J Neuropathol Exp Neurol; 2021 Nov; 80(11):1060–1067. PubMed ID: 34643702
[TBL] [Abstract][Full Text] [Related]
26. Electromyographic findings in sporadic inclusion body myositis.
Nojszewska M; Gawel M; Kierdaszuk B; Sierdziński J; Szmidt-Sałkowska E; Seroka A; Kamińska AM; Kostera-Pruszczyk A
J Electromyogr Kinesiol; 2018 Apr; 39():114-119. PubMed ID: 29482084
[TBL] [Abstract][Full Text] [Related]
27. Anti-Cytosolic 5'-Nucleotidase 1A in the Diagnosis of Patients with Suspected Idiopathic Inflammatory Myopathies: An Italian Real-Life, Single-Centre Retrospective Study.
Porcelli B; d'Alessandro M; Gupta L; Grazzini S; Volpi N; Bacarelli MR; Ginanneschi F; Biasi G; Bellisai F; Fabbroni M; Bennett D; Fabiani C; Cantarini L; Bargagli E; Frediani B; Conticini E
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509600
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers of inclusion body myositis.
Greenberg SA
Curr Opin Rheumatol; 2013 Nov; 25(6):753-62. PubMed ID: 24067380
[TBL] [Abstract][Full Text] [Related]
29. Update on Inclusion Body Myositis.
Jabari D; Vedanarayanan VV; Barohn RJ; Dimachkie MM
Curr Rheumatol Rep; 2018 Jun; 20(8):52. PubMed ID: 29955981
[TBL] [Abstract][Full Text] [Related]
30. Anti-cytosolic 5'-nucleotidase 1A (cN1A) autoantibodies in motor neuron diseases.
Liewluck T
Neurology; 2017 Nov; 89(19):2017-2018. PubMed ID: 28954884
[No Abstract] [Full Text] [Related]
31. [The etiology and pathogenesis of sporadic inclusion body myositis].
Murata KY; Ito H
Brain Nerve; 2014 Nov; 66(11):1385-94. PubMed ID: 25407074
[TBL] [Abstract][Full Text] [Related]
32. Positive Cytosolic 5-Nucleotidase 1A Antibodies in Motor Neuron Disease.
Assadi RK; Manousakis G
J Clin Neuromuscul Dis; 2020 Sep; 22(1):50-52. PubMed ID: 32833724
[TBL] [Abstract][Full Text] [Related]
33. Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
Rietveld A; van den Hoogen LL; Bizzaro N; Blokland SLM; Dähnrich C; Gottenberg JE; Houen G; Johannsen N; Mandl T; Meyer A; Nielsen CT; Olsson P; van Roon J; Schlumberger W; van Engelen BGM; Saris CGJ; Pruijn GJM
Front Immunol; 2018; 9():1200. PubMed ID: 29922285
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic features of sporadic inclusion body myositis in China.
Li K; Pu C; Huang X; Liu J; Mao Y; Lu X
Neurol Neurochir Pol; 2015; 49(4):245-50. PubMed ID: 26188941
[TBL] [Abstract][Full Text] [Related]
35. Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis.
Kramp SL; Karayev D; Shen G; Metzger AL; Morris RI; Karayev E; Lam Y; Kazdan RM; Pruijn GJ; Saschenbrecker S; Dähnrich C; Schlumberger W
Auto Immun Highlights; 2016 Dec; 7(1):16. PubMed ID: 27858337
[TBL] [Abstract][Full Text] [Related]
36. Clinical and Electrophysiological Findings in Hereditary Inclusion Body Myopathy Compared With Sporadic Inclusion Body Myositis.
Kazamel M; Sorenson EJ; Milone M
J Clin Neuromuscul Dis; 2016 Jun; 17(4):190-6. PubMed ID: 27224433
[TBL] [Abstract][Full Text] [Related]
37. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.
Dalakas MC; Rakocevic G; Schmidt J; Salajegheh M; McElroy B; Harris-Love MO; Shrader JA; Levy EW; Dambrosia J; Kampen RL; Bruno DA; Kirk AD
Brain; 2009 Jun; 132(Pt 6):1536-44. PubMed ID: 19454532
[TBL] [Abstract][Full Text] [Related]
38. High prevalence of inclusion body myositis in Norway; a population-based clinical epidemiology study.
Dobloug GC; Antal EA; Sveberg L; Garen T; Bitter H; Stjärne J; Grøvle L; Gran JT; Molberg Ø
Eur J Neurol; 2015 Apr; 22(4):672-e41. PubMed ID: 25530508
[TBL] [Abstract][Full Text] [Related]
39. Advances in serological diagnostics of inflammatory myopathies.
Benveniste O; Stenzel W; Allenbach Y
Curr Opin Neurol; 2016 Oct; 29(5):662-73. PubMed ID: 27538058
[TBL] [Abstract][Full Text] [Related]
40. Sporadic inclusion body myositis: clinical, pathological, and genetic analysis of eight Polish patients.
Kierdaszuk B; Berdynski M; Palczewski P; Golebiowski M; Zekanowski C; Kaminska AM
Folia Neuropathol; 2015; 53(4):355-66. PubMed ID: 26785370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
